IBDEI2FL ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41238,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,41238,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,41239,0)
 ;;=D09.0^^159^2004^39
 ;;^UTILITY(U,$J,358.3,41239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41239,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,41239,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,41239,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,41240,0)
 ;;=D06.9^^159^2004^40
 ;;^UTILITY(U,$J,358.3,41240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41240,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,41240,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,41240,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,41241,0)
 ;;=D06.0^^159^2004^42
 ;;^UTILITY(U,$J,358.3,41241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41241,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,41241,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,41241,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,41242,0)
 ;;=D06.1^^159^2004^43
 ;;^UTILITY(U,$J,358.3,41242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41242,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,41242,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,41242,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,41243,0)
 ;;=D06.7^^159^2004^41
 ;;^UTILITY(U,$J,358.3,41243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41243,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,41243,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,41243,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,41244,0)
 ;;=D04.9^^159^2004^44
 ;;^UTILITY(U,$J,358.3,41244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41244,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,41244,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,41244,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,41245,0)
 ;;=C91.11^^159^2004^47
 ;;^UTILITY(U,$J,358.3,41245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41245,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,41245,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,41245,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,41246,0)
 ;;=C91.10^^159^2004^48
 ;;^UTILITY(U,$J,358.3,41246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41246,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,41246,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,41246,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,41247,0)
 ;;=C92.11^^159^2004^49
 ;;^UTILITY(U,$J,358.3,41247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41247,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,41247,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,41247,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,41248,0)
 ;;=C92.10^^159^2004^50
 ;;^UTILITY(U,$J,358.3,41248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41248,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,41248,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,41248,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,41249,0)
 ;;=D47.1^^159^2004^51
 ;;^UTILITY(U,$J,358.3,41249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41249,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,41249,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,41249,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,41250,0)
 ;;=C82.69^^159^2004^52
 ;;^UTILITY(U,$J,358.3,41250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41250,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,41250,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,41250,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,41251,0)
 ;;=C82.60^^159^2004^53
